Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets

Table 3 Clinical trials with chimeric antigen receptor T cells cells in hepatocellular carcinoma

NCT	Antigen	Phase	Patients	Sponsor	Status	Comments
NCT02715362	GPC3	I/II	30	Company	Recruiting	HAI
NCT03672305	c-Met/PD-L1	I	50	Academic	Not yet recruiting	IV
NCT02723942	GPC3	I/II	60	Academic	Completed
NCT03198546	GPC3	I	30	Academic	Recruiting
NCT02395250	GPC3	I	13	Academic	Completed	[58]
NCT03349255	AFP	I	18	Company	Recruiting	IV vs HAI
NCT03130712	GPC3	I/II	10	Company	Recruiting	IT
NCT03084380	GPC3	I/II	20	Academic	Not yet recruiting	Combination with TACE
NCT029051881	GPC3	I	14	Academic	Not yet recruiting
NCT03302403	GPC3	I	48	Academic	Not yet recruiting
NCT03146234	GPC3	I	20	Academic	Recruiting
NCT01935843	Her2	I/II	10	Academic	Unknown
NCT02959151	GPC3	I/II	20	Company	Unknown
NCT02587689	MUC1	I/II	20	Company	Unknown
NCT03013712	EpCAM	I/II	60	Academic	Recruiting

¹Location of study is United States, all other trials are conducted in China. HAI: Hepatic artery infusion; IT: Intratumoral injection; IV: Intravenous injection; TACE: Transarterial chemoembolization.